Afsaneh Barzi, MD, PhD, is a medical oncologist specializing in the treatment of gastrointestinal cancers at City of Hope Comprehensive Cancer Center, in Duarte, CA.
Dr Barzi earned her medical degree at Tehran University of Medical Science, in Tehran, Iran before completing a residency in internal medicine and earning a PhD in public health at the University of Texas, in Austin, TX. Following this, she completed a fellowship in hematology and oncology at the Cleveland Clinic Taussig Cancer Center, in Cleveland, OH.
She is a member of the Alliance Cancer Care Delivery Committee, the SWOG Gastrointestinal Committee and Cancer Care Delivery Committee, as well as the American Society of Medical Oncology (ASCO). Her work has been recognised with various accolades, including the Young Investigator Award from the Southwestern Oncology Group in 2011 and the Travel Award for Markers in Cancer in 2013.
Speaking on novel therapeutics for the treatment of gastrointestinal cancers
Dr Barzi’s research focuses on the development of new cancer therapies for the treatment of gastrointestinal cancers affecting the colon, rectum, pancreas, stomach and liver. She has been involved in several clinical trials, notably the recent Phase II trial investigating the safety and efficacy of neoadjuvant bevacizumab with modified FOLFOX7 for the treatment of patients with stage II and III rectal cancer (NCT01871571). In addition, her research interests include healthcare economics and the metrics of healthcare quality for improving patient care.